The introduction of new-age antidiabetic drugs; such as Dipeptidyl peptidase-4 (DPP-4) inhibitors had fundamentally changed the treatment settings for type 2 diabetes mellitus (T2DM). DPP-4 inhibitors elevate endogenous glucagon-like peptide-1 concentrations, stimulating insulin secretion, and inhibiting glucagon secretion.
DPP-4 inhibitors possess a favorable safety profile, do not elevate intrinsic hypoglycemia risk and have demonstrated cardioprotective and nephroprotective benefits.1 Many national and international guidelines including The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) have incorporated DPP-4 inhibitors are positioned as second-line therapy. Moreover, they are recommended in triple therapies as well.1,2 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-specialty Panel discussion on 16th…